Curriculum Vitae
798
Fauna Road. NECSA
(Building 1600)
Florauna PO
Box 582
0182 Pretoria
+27
(0)84 754 7834 +
27 (0)12 305 5786
Educational qualifications
School : Matriculated from Hoërskool
Noord-Oosrand
University : University of Pretoria
Year : 1991-1994
Degrees
obtained : BSc (with distinction), 1993
: BSc(Honours) in Chemistry with
distinction, 1994
(Part
time while employed at NECSA)
University : University of Cape Town
: MSc in Chemistry, 1997
University : Delft
University of Technology (The Netherlands )
: PhD, 2001
EANM Postgraduate Diploma for
Radiopharmaceutical Chemistry / Radiopharmacy:
·
Module
III: CEA/INSTN, Saclay, France, 2009
Prizes received
Departmental
Chemistry prize
|
:
|
Various
prizes as best undergraduate Chemistry student
|
The SACI
James Moir Medal
|
:
|
Best
performance in Chemistry at honours level if graduated with distinction. 1994
|
Young
Investigator Travel Award to attend the12th International Congress of
Radiation Research
|
:
|
Award to
travel to the conference for investigators
within in 5 years of reward of last degree
August 17 –
22, 2003 Brisbane, Australia
|
The SACI
Raikes Medal 2007
|
:
|
Chemical researcher in
|
NRF Rating : C3 (2008-2014)
Employment
NECSA : 1995 –
South
African Nuclear Energy
Corporation
(previously AEC of SA)
Current
position : Head of Radiochemistry
Scope of work: Institutional : Development of new radiopharmaceutials
used in the
treatment of secondary bone metastasis
Commercial : Development
of isotope production methods to exploit the use
of the SAFARI-I research reactor for commercial ends
North
West University (CARST) : Extraordinary Associate Professor
(2006-2010)
North
West University : Extraordinary Associate Professor
(2011-2013)
(Drug Research and
Development)
Publications (39 of which 36 in ISI accredited journals),
books (1) and chapters in books (4)
>50 conference
publications 8 Invited lectures of which 4 where plenary/keynote lectures
J.R. Zeevaart, N.V. Jarvis, I. Cukrowski and G.E.
Jackson. Blood plasma modelling of the in
vivo behaviour of bisphosphonate-metal-ion complexes as
radiopharmaceuticals. S. Afr. J. Chem.,
1997, 50, 189-194.
Citations: 18 Impact
factor: 0.567
I. Cukrowski, J.R. Zeevaart and N.V. Jarvis. A
potentiometric and differential pulse polarographic study of CdII
with 1-hydroxyethylenediphosphonic acid. Anal.
Chim. Acta, 1999, 379, 217-226.
Citations: 21 Impact
factor: 4.114
J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, G.E. Jackson
and R Mouton. Metal-ion speciation in blood plasma incorporating the
biphosphonate, 1-hydroxy-4-aminopropilydenediphosphonate (APD), in therapeutic
radiopharmaceuticals. J. Inorg. Biochem.,
1999, 73, 265-272.
Cited by KH Thompson & C
Orvig in Boon and Bane of Metal ions in Medicine, Science 2003, 300 , 936-939 (IR Zeevaart and not JR
Zeevaart)
Citations: 35 Impact
factor: 3.495
J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener,
I.C. Dormehl and R.J. Milner. Comparison between blood plasma models (ECCLES)
for 153Sm and 166Ho complexed to diphosphonate ligands
(possible radiotherapeutic bone agents) and their in vivo behaviour as studied in non-human primates. Isotope
Production and Applications in the 21st Century, N.R. Stevenson, World Scientific, 2000, 403-406, ISBN:981-02-4200-x.
Citations: 0 Chapter
in book
J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw and G.E.
Jackson. Metal-ion speciation in blood plasma incorporating the
tetraphosphonate, N,
N,-dimethylenephosphonate-1-hydroxy-4-aminopropily-denediphosphonate (APDDMP),
in therapeutic radiopharmaceuticals. J.
Inorg. Biochem., 2001, 83,
57-65.
Citations: 27 Impact
factor: 3.495
J.R.
Zeevaart, W.K.A. Louw, N.V. Jarvis and J.M. Wagener. Comparison of the
predicted behaviour of 153Sm, 166Ho and 117mSn
containing bone agents, employing blood plasma models (ECCLES), with in vivo results as studied in animals. J. Lab. Comp. Radiopharm., 2001, 44, suppl 1, S799-S801.
Citations: 1 Impact
factor: 0.913
J.R.
Zeevaart, Metal-ion speciation in blood plasma as a tool in predicting the in vivo behaviour of potential
bone-seeking radiopharmaceuticals. PhD Thesis, Delft University Press, 2001, ISBN 90-407-2242-0. Nr of pages 163
Citations: 4 Book
N.V. Jarvis, J.R. Zeevaart, J.M. Wagener, W.K.A. Louw,
I.C. Dormehl, R.J. Milner and E. Killian. Metal-ion speciation in blood plasma
incorporating the water-soluble polymer, polyethyleneimine functionalised with
methylene-phosphonate groups, in therapeutic radiopharmaceuticals. Radiochimica Acta, 2002, 12,
237-246.
Citations: 5 Impact
factor: 1.459
J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener,
Z.I. Kolar and R.A.M.J. Claessens. Speciation studies of SnII in
blood plasma incorporating proposed bone-seeking ligands as potential
therapeutic radiopharmaceuticals. Journal
of Radioanalytical and Nuclear Chemistry, 2003, 257, 83-91.
Citations: 11 Impact
factor: 1.52
J.R.
Zeevaart, W.K.A. Louw, Z.I. Kolar, E. Kilian, F.E. Jansen van Rensburg, I.C.
Dormehl. Biodistribution and pharmacokinetics of variously molecular sized 117mSn(II)-polyethyleneiminomethyl
phosphonate (PEI-MP) complexes in the normal primate model as a potential
selective therapeutic bone agent. Arzneimittel-Forschung/Drug Research, 2004, 54, 340-347.
Citations: 12 Impact
factor: 0.632
T.E. Nomkoko, G.E. Jackson, B.S. Nakani, W. K. A. Louw, J.R. Zeevaart.
Thermodynamic and biodistribution studies of Zn(II), Ca(II),Gd(III) and Cu(II)
complexes of 3,3,9,9-tetramethyl-4,8-diazaundecane-2,10-dione dioxime. J. Chem. Soc. Dalton, 2004, 741-749.
Citations: 3 Impact
factor: 3.838
J.R. Zeevaart, D.R. Jansen, M.F. Botelho, A.
Abrunhosa, C. Gomes, L. Metello, Z.I. Kolar, G.C. Krijger, W.K.A. Louw, I.C.
Dormehl. Comparison of the predicted in vivo behaviour of the Sn(II)-APDDMP
complex and the results as studied in a rodent model. J. Inorg.
Biochem. 2004, 98, 1523-1530.
Citations: 6 Impact
factor: 3.495
I.
Cukrowski, D.M. Mogano, J.R. Zeevaart. Voltametry as a virtual potentiometric
sensor in modelling of a metal-ligand system and refinement of stability
constants. Part 4. An electrochemical study of NiII complexes with
methylene disphosphonic acid. J. Inorg.
Biochem. 2005, 99, 2308-2321.
Citations: 6 Impact
factor: 3.495
J.R. Zeevaart, S.A. Shady, A. Goede, M.M. Phetoe, Determination of adsorption characteristics for
different Cs selective resins, Proceedings of the 5th International
Conference on Isotopes, Editors; H. Bonet, B.J. Allen, C. Chemaly, Medimond, 2005, ISBN 88-7587-186-8,
227-230.
Citations: 0 Chapter
in book
J.R.
Zeevaart, S. Olsen. Recent trends in the concept of specific activity: Impact
on radiochemical and radiopharmaceutical producers. Applied Radiation and Isotopes, 2006, 64, 812-814.
Citations: 6 Impact
factor: 1.202
M.F. Botelho, F. Caramelo, C. Gomes, J.R. Zeevaart , W.K.A.
Louw , I.C. Dormehl, Z.I. Kolar , G.C. Krijger ,
R.J. Milner. 117mSn-APDDMP for Osteosarcoma Treatment. Biodistribution and
Dosimetric Considerations. Radioprotecção (Radioprotection - The official
journal of the Portuguese Health Physics Society), 2006, vol 2, nr. 8&9 ISSN-0874-7016
Citations: 0 (Non ISI)
J. van Rooyen, Z. Szucs, J.R. Zeevaart. A possible
in vivo generator 103Pd/103mRh - Recoil considerations. Applied Radiation and Isotopes, October 2008, 66(10), 1346-1349.
Citations: 6 Impact
factor: 1.202
D. R. Jansen, J. R. Zeevaart, Z. I. Kolar, K.
Djanashvili, J.A. Peters, G. C. Krijger. P-31 NMR study of the valence
stability of Tin in its 1-hydroxyethylene-diphosponate (HEDP) and
N,N’,N’-trimethylenephosphonate-polyethyleneimine (PEI-MP) complexes. Polyhedron, 2008, 27, 1779–1786.
Citations: 6 Impact
factor: 2.118
J.M. Wagener, M. K. Dithebe, M.D. Mogano, I.
Cukrowski, J.R. Zeevaart. Modelling of the blood plasma species of biguanide
derivates exhibiting potential as diagnostic radiopharmaceuticals. South African Journal of Chemistry, 2008,
61, 82-92.
Citations: 1 Impact
factor: 0.567
Z. Szucs , D. Steyn, E.
Vermeulen, I.J. Van der Walt, K. Moodley, S. Verryn. J.R. Zeevaart. Separation
of 103Pd from metal Rh by thermal diffusion impossible. 7th International Conference on
Nuclear and Radiochemistry. NRC 7. Budapest, Hungary, 24-29 Aug., 2008.
Proceedings. CD-ROM 0 (2008)1-1./ 0.000
Citations: 2 Chapter in book
D. Jansen, J.R. Zeevaart, A. Denkova, Z. Kolar, G Krijger. The
Hydroxyapatite Chemisorption of N,N',N'-trimethylenephosphonate-polyethyleneimine
(PEI-MP) Combined with Sn2+ or Sn4+. Langmuir
2009, 25, 2790 – 2796.
Citations: 3 Impact
factor: 4.186
M.J. Nell, J.M. Wagener, J.R. Zeevaart, E. Kilian, M.A.
Mamo, M. Layh, M. Coyanis, C.E.J. van Rensburg. The anti-tumour properties and
biodistribution (as determined by the radiolablled equivalent) of Au-compounds
intended as potential chemotherapeutics Applied Radiation and Isotopes. 2009, 67, 1370–1376.
Citations: 3 Impact
factor: 1.202
Z. Szucs, J. Van Rooyen, J.R. Zeevaart. Recoil effects
on ß-decaying in vivo generators, interpreted for 103Pd/103Rh.
Applied Radiation and Isotopes. 2009, 67,
1401-1404.
Citations: 6 Impact
factor: 1.202
J.R. Zeevaart, J.M.
Wagener, M. Neves, M.C. Costa, C. Rodrigues, M. Dithebe, E. Kilian, I.
Cukrowski. 99mTc-labelled biguanide derivatives: chemical speciation
modelling thereof and evaluation in vervets; J Radioanal Nucl Chem. 283,
2010, 123-131.
Citations: 2 Impact
factor: 1.52
D.R. Jansen, G.C. Krijger,
J. Wagener, R.M. Senwedi, K. Gabanamotse, M. Kgadiete, Z.I. Kolar, J.R.
Zeevaart. Blood plasma model predictions
for the proposed bone-seeking radiopharmaceutical [117Sn]Sn(IV)-N,N,N’-trimethylenephosphonate-poly(ethyleneimine);
Journal of Inorganic Biochemistry,
2009, 103,1265-1272.
Citations: 1 Impact
factor: 3.495
Janine Suthiram, Kanyisa Mhlaba, Jan Rijn Zeevaart,
Hendrik G Visser and Andreas Roodt, Tetrathylammonium
tricarbonly-chlorido(pyrazine-2-carboxylato-N1, O) – rhenate (I) Acta Cryst E, 2009, E 65, m1395 Citations:
1 Impact
factor: 0.35
Zoltan Szucs, Danie Moolman, Sabine Verryn, Jan Rijn
Zeevaart, The metal Rhodium does not have allotropes, Journal of Radioanalytical and Nuclear Chemistry, 284 (1), 2010, 239-243.
Citations: 1 Impact
factor: 1.52
Zoltan Szucs, Mike Sathekge, Biljana
Marjanovic-Painter, Judith Wagener, Thato Sello, Carl Wagener, Jan Rijn
Zeevaart. Synthesis of I-131
Labelled 4-Iodo-Phenyl-Acetic acid Journal
of Labelled Compounds and Radiopharmaceuticals, 2010, 54, 54-58.
Citations: 1 Impact
factor: 1.24
Janine Suthiram, Jan Rijn Zeevaart, Hendrik G Visser
and Andreas Roodt, Tetrathylammonium
tricarbonly-chlorido(quinoxaline-2-carboxylato-N1, O) – rhenate (I) Acta Cryst E, 2010, E 66. m1042-m1043.
Citations: 0 Impact
factor: 0.35
MF Botelho, AM Abrantes, JR Zeevaart , DR Jansen, A
Turtoi , ZI Kolar, M Neves, FHA Schneeweiss, GC Krijger, IC Dormehl. Comparison
of the Therapeutic Potential of the Polyphosphonate Pei-Mp Labeled with 99mtc,
117msn, 186re and 188re. Acta Médica Portuguesa, II Série, 2010, 23,
313.
Citations: 0 Impact
factor: 0.256
David R Jansen, Gerard C. Krijger, Zvonimir. I. Kolar,
Bernard A. Zonneberg, Jan Rijn Zeevaart Bone targeting in the radiotherapeutic
treatment of bone malignancies. Current Drug Discovery Technologies 2010; 7(4): 233-246.
Citations: 11 Impact
factor: 4.90
Jan Rijn Zeevaart, Zoltan Szucs, Sandor Takacs, Neil
V. Jarvis, David. R. Jansen. Recoil and conversion electron considerations of
the 166Dyl166Ho in vivo generator. Radiochimica Acta. 2012, 100, 109-113.
Citations: 1 Impact
factor: 1.459
O.D. Maslov, G. Ya. Starodub, G.K. Vostokin, M.V.
Gustova, S.N. Dmitriev, V.N. Shvetsov, S. Takacs, Z. Szucs, D. Jansen, J.R.
Zeevaart. The production of 117mSn with high specific activity by
cyclotron. Applied Radiation and Isotopes,
2011, 69 (7), 917-1102.
Citations: 2 Impact
factor: 1.202
Sepini, L., Jarvis, N.V., Jansen, D.R., Zeevaart, J.R. Thermodynamic
evaluation of the stability of the bone-seeking radiopharmaceutical
[117Lu]Lu(III)-DOTP under simulated blood plasma conditions. Analitica Chimica Acta. 730 (2012) 66– 70 http://dx.doi.org/10.1016/j.aca.2011.10.068
Citations: 0 Impact
factor: 4.114
Jan Rijn Zeevaart,
Zoltan Szucs, Tamsyn Pulker, Thato Sello, Jacqueline Bracher, Mike Sathekge. Biodistribution and pharmacokinetics of
I-131 labelled 4-Iodophenulacetic acid. Current
Radiopharmaceuticals. 5 (2012) 356-362
doi:
10.2174/1874212222801184710
Citations: 1 Impact
factor: 0.69 (non ISI)
Jan Rijn Zeevaart, Zoltan Szucs, Sandor Takacs, Johann
van Rooyen, David Jansen. Recoil and conversion electron implications to be
taken into account in the design of therapeutic radiopharmaceuticals utilising
in vivo generators. Journal of Labelled
Compounds and Radiopharmaceuticals, 2012, 55, 115-119
Citations: 0 Impact
factor: 1.24
B Kweto, DR Groot,
J Suthiram, L Stassen, JR Zeevaart. The use of ammonium carbonate as lixiviant
in uranium leaching. ALTA 2012
conference on nickel/cobalt/copper, uranium & gold. 26 May- 2 June 2012,
Perth, Australia. Proceeding of Uranium
sessions at ALTA 2012,
ISBN: 978-0-9871262-4-5, p.139-149
Citations: 0 Chapter in book
Venter, L., Jansen, D.,
Wagener, J., Fourie, P.B., Zeevaart, J.R.
Characterization of radiolabelled dry powder leucine, a constituent of
inhalable capreomycin. Drug delivery letters. 2 (2012) 155-161
Citations: Impact
factor: new journal non ISI
Matthew P.
Akerman, Orde Q. Munro, Modisenyane Mongane, Johan A. van Staden, William I. D.
Rae, Cornelius J. Bester, Biljana Marjanovic-Painter, Zoltan Szucs and Jan Rijn
Zeevaart. Schiff base complex: a potential chemotherapeutic Biodistribution
(as determined by the radiolabelled equivalent) of a gold(III)
bis(pyrrolide-imine). Journal of Labelled
Compounds and Radiopharmaceuticals, 56 (2013) 495-503.
Citations: 0 Impact
factor: 1.24
Jan Rijn Zeevaart, Judith Wagener, Biljana Marjanovic-Painter, Mike
Sathekge, Nischal Soni, Christa Zinn, Gary Perkins, Suzanne Smith. "Production
of high specific activity 195mPt-cisplatinum at Necsa for Phase 0
clinical trials in healthy individual subjects" Journal
of Labelled Compounds and Radiopharmaceuticals, 56 (2013) 530–535.
Citations: 0 Impact
factor: 1.24
Thomas Ebenhan, Jan Rijn
Zeevaart, Kobus J Venter, Thavendrian Govender, Gert H. Kruger and Mike M.
Sathekge. Preclinical
Evaluation of a Promising Infection Imaging PET/CT Biomarker: Feasibility Study
of 68Ga-labeled UBI29-41-1,4,7-triazacyclononane-1,4,7-triacetic
Acid in a New Zealand Rabbit Model. Journal
of Nuclear Medicine. Published January 16, 2014 as
doi:10.2967/jnumed.113.128397.
Citations: 0 Impact
factor: 5.774
M Sathekge, J Wagener, S V
Smith , N Soni, B Marjanovic-Painter, C Zinn , C Van de Wiele, Yves D’Asseler, G Perkins, J R Zeevaart "Biodistribution and dosimetry of 195mPt-cisplatin,
a single photon emission computed tomography imaging agent in normal
volunteers." Nuklearmedizin, (2013) 52, 222-227.
Citations: 0 Impact
factor: 1.322
Thomas
Ebenhan, Nicholas Chadwick, Mike M. Sathekge, Patrick Govender, Thavendran
Govender, Hendrik G. Kruger, Biljana Marjanovic-Painter and Jan Rijn Zeevaart. Peptide synthesis, characterization and 68Ga-radiolabeling
of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with
PET/CT. Nuclear Medicine and Biology.
accepted for publication.
Citations: 0 Impact
factor: 3.023
Frederik H. Kriel, Zoltan Szucs, Johan A.
van Staden, Cornelius J. Bester,
Modisenyane Mongane, Sebastiaan Lamprecht, William I. D. Rae, Jan-Rijn
Zeevaart. Biodistribution of a potential chemoteraputic, dinuclear
bisphosphinogold(I) dithiocarbamate, as determined by its Au-198 radiolabelled
analogue. Journal of Radioanalytical and
Nuclear Chemistry, submitted for publication.
Citations: 0 Impact
factor: 1.467
CARBON-14 RADIOLABELLING AND IN VIVO BIODISTRIBUTION
OF A POTENTIAL ANTI-TB COMPOUND. Molahlehi S. Sonopo, Kobus Venter, Suzan
Winks, Biljana Marjanovic-Painter and Jan Rijn. Zeevaart. Journal of Labelled Compounds and
Radiopharmaceuticals, submitted for publication.
Citations: 0 Impact
factor: 1.24
Optimisation of the Necsa in-house 195mPt-cisplatinum
synthesis method.Judith Wagener,
Biljana Marjanovic-Painter and
Jan Rijn. Zeevaart. Confidential report
nr. RC-TRAPT195-REP-10001 accepted
for publication.
Citations:
0 Internal
peer- reviewed report
Patents
DR Jansen, GC Krijger, ZI Kolar, JR
Zeevaart. Method of producing Radionuclides. WO2011/111010. Patent granted in toto.
JR Zeevaart, XY Mbianda, Z Szucs.
Anticancer agent. PCT Patent Application No. WO 2013/005154. Examination successfully completed.
JR Zeevaart, AF Grobler. Pharmaceutical
composition. South African Provisional Patent
Application No. 2013/08240 filled on 4 November 2013.
JR Zeevaart, Z Szucs, JM Wagener, A Pillay. A method of producing ethylenedicysteine deoxyglucosamine (ECDG) and
its kit formulation. UK provisional patent filed on 2014/02/07
JR Zeevaart, C Driver, DR Jansen, R Hunter,
I Parker. Bone agent. In process to file a UK provisional patent.
JSF Botha, JR Zeevaart. TRANSFER VESSEL FOR
USE IN TRANSFERRING PRODUCTS BETWEEN RADIATION CONTAINMENT CHAMBERS In process
to file a UK provisional patent.
Student Supervision
Student
name
|
Degree
|
Role
|
Period
|
Mildred Dithebe
|
MSc, NWU
|
Co-Supervisor
|
2000-2002
|
Kenneth Gabanamotse
|
MSc, NWU
|
Supervisor
|
2003-2004
|
Ratanang Senwedi
|
MSc, NWU
|
Supervisor
|
2004-2005
|
David Jansen
|
MSc, UCT
|
Co-Supervisor
|
2005-2007
|
David Jansen
|
PhD, TU Delft
|
Supervisor
|
2007-2011
|
Njabuliso Dlamini
|
MSc, UJ
|
Co-Supervisor
|
2009-2011
|
Janine Suthiram
|
MSc, UFS
|
Co-Supervisor
|
2010-2011
|
Lebogang Sepini
|
MSc, NWU
|
Supervisor
|
2010-2012
|
Tsekiso Ranqhai
|
MSc, UJ
|
Co-Supervisor
|
2010-2013
|
Braam Swanepoel
|
PhD, NWU
|
Co-Supervisor
|
2011-2013
|
Paul Grobler
|
PhD, NWU
|
Co-Supervisor
|
2011-2013
|
Thomas Ebenhan
|
Postdoc, UKZN
|
Supervisor
|
2010-2012
|
Molahlehi Sonopo
|
Postdoc
|
Supervisor
|
2011-2013
|
Adushan Pillay
|
Postdoc
|
Supervisor
|
2012-2014
|
Nick Chadwick
|
MSc, UKZN
|
Co-Supervisor
|
2010-2013
|
Cathryn Driver
|
PhD, UCT
|
Co-Supervisor
|
2010-2014
|
Njabuliso Dlamini
|
PhD, UJ
|
Co-Supervisor
|
2012-
|
Brenda Mokaleng
|
PhD, UP
|
Co-Supervisor
|
2011-
|
Isabel Schoeman
|
MSc, NWU
|
Supervisor
|
2011-2013
|
Jenine Horn
|
PhD, UFS
|
Co-Supervisor
|
2012-
|
Kefilwe Thoane
|
MSc, NWU
|
Supervisor
|
2011-
|
Vusy Mandiwana
|
MSc, NWU
|
Supervisor
|
2012-2013
|
Jolanda Ackerman
|
PhD, UJ
|
Co-Supervisor
|
2013-
|
Clinton Rambapanasi
|
PhD, NWU
|
Co-Supervisor
|
2013-
|
Nomasonto Rapulenyane
|
PhD, UP
|
Supervisor
|
2013-
|
Vusy Mandiwana
|
PhD, NWU
|
Supervisor
|
2014-
|
Cathryn Driver
|
Postdoc
|
Supervisor
|
2014-
|
Adele van As
|
MSc, NWU
|
Supervisor
|
2014-
|
Funding applications
NRF incentive funding for rated researchers
2011-2014; R40 000 per year. UID: IFR2011032800058
2013 NRF Mobility Travel Grant, R45 000
- UID: 82514
2013 NRF RISP programme Sample oxidiser R 1
254 000 - UID: 86070
2013-2015 NRF PDP (PhD) R
200 000/year - UID: 86131
2013-2015 NRF PDP (PhD) R
200 000/year – UID: 86132
2013-2014 NRF PDP (Postdoc) R
300 000/year – UID: 86134
2012-2014 NRF PDP (Postdoc) R
300 000/year – UID: 80724
2011-2013 NRF PDP (Postdoc) R
300 000/year – UID: 77940
2009-2010 SA-Hungary bilateral R138 000
- UID: 68768
2007-2009 KISC (‘An
in vitro instead of in vivo approach to develop bone-seeking
radiopharmaceuticals as carried out in the Netherlands and South Africa: 117mSn(IV)-ligand
complexes’) R249 897 - UID:
63754
2007 NRF RISP programme; Remote synthesiser
and HPLC. R 1 347 000 - UID: 65277
2006-2009 NWO Wotro funding from the
Netherlands (Mobility for PhD of DR Jansen at TU Delft) 55 000 Euro
THRIP
acted as industry partner.
Prof HG Kruger. UKZN, Westville campus, Chemistry dept.
Dr Xavier Mbianda. UJ, Doornfontein campus,
Chemical Technology dept.
DST
FP6 seed funding
Completed
research
1.A long standing research interest of
myself (which stems from my PhD) is to reduce the number of animal
experimentation in radiopharmaceutical drug development. This can be achieved
by using an in silico rather than in
vivo approach through the establishment of models based on lab chemical
procedures. This focussed on the development of new bone seeking
radiopharmaceuticals. Over the years Ho-166, Sm-153, Lu-177 and Sn-117m have
been included in such a model. In the last 8 years the work focussed on Sn-117m
and Lu-177. The established models are based on thermodynamic principles
(adsorption on hydroxyl apatite through measurement of the Langmuir equations
and blood plasma though the measurement of formation constants) as well as
lately kinetic principles by the measurement of to formation rates. Together
one is able to elucidate the behaviour of the proposed radiopharmaceutical
before it is tested. For the Sn(IV) PEI-MP (a phosphonate polymer that will
accumulate passively in tumour areas due to its size making it only possible to
escape from vasculature in tumorous area where the blood vessels are ruptured –
the so called EPR effect ) system 3 papers in high impact journals (Polyhedron,
Langmuir and J. Inorg. Biochem) demonstrated that animal studies should not be
pursued. Also of note was the paper in Polyhedron which showed that Sn(II) if
complexed to a ligand such as a bisphosphonate does not oxidise readily in vivo
to Sn(IV) as is generally asumed. All these results were combined in a review
paper in the journal Current Drug Discovery Technologies in 2010 Furthermore
over this whole period 10 conference presentations of which 5 were recorded in
proceedings, were also presented.
2.For Lu-177 a Lu(III) blood plasma model
has been recently drafted and validated. It explains the clinical success of
Lu-177 EDTMP. The results were published in a high impact journal (Anal Chim
Acta) which also indicates that DOTP will be a very suitable replacement for
EDTMP.
3.A similar methodology was used for the
first time for new potential Tc-99m based kidney imaging agents although the
formation constants for Tc cannot be measured. The formation constants were
published in the SA J Chem and the blood plasma model as well as the
preclinical work that proved the model to make accurate in vivo predictions was
published in the J Radioanal Nucl Chem.
Our thermodynamic approach was then extended to include kinetic results
during the investigation of new bidentate ligands for coordination of Tc/Re
tricarbonyl cores. This was successfully achieved and two crystal structures
were recorded which were published. The kinetic evaluation is still has to be
published.
4.Production of Sn-117m which is a short
range emitter and therefore ideal for treating bone metastasis has also
received attention over the last eight years. Apart from the selective
accumulation of PEI-MP it requires high specific activity Sn-117m to ensure
enough activity can be administered. One way of doing this is by using carbon
to capture recoiling Sn-117m in nuclear reactor. This was patented in WO2011/111010 that was
awarded in toto. Another way to
achieve this is by the alpha bombardment of a Cd target which was performed in
a collaborative effort with JINR, Dubna, Russia which was published in Appl Rad
Isotop.
5.As a scientist that is always looking for
new opportunities I started to interact with Prof Mike Sathekge, head of Nucl.
Med (University of Pretoria) at the Steve Biko Academic Hospital. It has been a
very fruitful collaboration. He suggested that I-131 labelled phenyl acetic
acid would be a good anticancer agent. Phenyl acetic acid is a metabolite that
is used by cancerous cell at elevated levels. On its own it is in phase 3
clinical trials. An additional I-131 on the molecule would make for an
interesting combination therapy which has always been one of my research
interests. The radiolabelling was published in J Lab Comp Radiopharm and the
preclinical evaluation in xenografted mice was published in Current Radiopharm.
Although no unwanted target organs were identified and the drug would
potentially be safe for use in humans a low tumour to background ratio of 2 was
recorded. The conclusion was unfortunately that compound will not be feasible
as radiotherapeutic agent. However this whole exercise taught myself and
co-workers involved the principles of xenograft studies.
6.Based on the positive results achieved
with PEI-MP and the EPR effect a project was started to exploit the EPR effect
using nanoparticles. This is a world first to marry radiopharmacy and
nano-particles exploiting the EPR effect to passively accumulate a smart bomb
in bone metastasis. To avoid completion of blood plasma metal ions as was
explained above and that nano-particles coordinate poorly to metal ions it was
opted for covalently bonded radiophosporous. P-32 has a long range which might
not be ideal as bone agent as it would cause damage to surrounding bone marrow,
however the short range P-33 could act as replacement. At the time P-32 was
produced on the Pelindaba site which made the research easy and desirable to
provide new markets for the radioisotope. The synthesis was successful and a
patent was filled which was successfully examined, WO 2013/005154. This now
requires clinical testing and commercial exploitation.
7.Apart from being involved with research
that is applied science and aimed at products over the short and medium term
there is always the desire to do more fundamental research. This opportunity
came after reading on the idea of in vivo generators. The concept has high
potential and uses the concept that a short lived daughter can be used in vivo
if its longer lived mother nuclide can be allocated in the target organ
providing little damage to the rest of the body while localising in the target
organ (tumour) whereafter the daughter decays and does the damage to the tumour
cell. I have always believed that short range emitters will be the best answer
for therapeutic radiopharmaceuticals. Auger emitters are most suitable for
this. The isotope that is a very favourable exponent of this is Rh-103m but its
half life is 56 min which makes it impossible to locate in the target in time.
However Pd-103 can act as the mother nuclide of this in vivo generator. One
problem that is recorded in the literature with this concept is that the
chelator that holds the mother nuclide may not lose the daughter nuclide upon
decay and resulting recoil. For alpha emitters this phenomena is well known. In
collaboration with others a universal equitation for all beta/gamma and auger
emitters was developed. This was then tested for the in vivo generator Sr/Y-90
which validated our equation and Dy/Ho-166 for which we calculated it should
experience no loss from the DOTA chelator. To our surprise 70% recoil was
experienced which coincided with the 70% of relaxation which happens via the
Auger emission. The latter is responsible for fragmentation of the chelator.
This will therefore also happen to the Pd-103/Rh-103m generator. This implies a
delocalised chelator for Pd(II) will have to be designed to make it feasible. 4
papers have been published the most important in J Lab Comp Radiopharm in 2012
and this also presented as an invited plenary speaker at ARCEBS 2010
8.Au compounds are a niche research area in
SA which is a big gold producer. In this period three compounds which are very
toxic in vitro towards cancer cell lines, were radiolabeled with Au-198 and
pre-clinically evaluated in rats. In all cases the result was that the
compounds have high affinity for liver and/or lung which makes them unsuitable
for further evaluation. Although disheartening for the researchers involved
this is vital information from a cost perspective. Two papers appeared; in Appl
Rad Iso and J Lab Comp Radiopharm.
9.The next step in my growth was clinical
evaluation for which a GMP clean room was established upon my initiative.
Platinum agents (such as cisplatin) continue to be the main chemotherapeutic
agents used in treatment of cancer patients. However the side effects are well
known and often patients suffer form to incorrect doses being administered. It
is important to optimize the dose given to each patient. After two years and a
big team effort Pt-195m-cisplatinum , GMP compliant, was produced and
administered to ten healthy volunteers as part of an ethical approved phase 0
clinical trial. The majority of the injected dose was excreted in the urine
within 5 h post injection. A wide range of urinary excretion (between the 10
volunteers) was found which demonstrated the potential of Pt-195m-cisplatinum
to be used as companion diagnostic to optimise patients dose. These results
were published in 2013 in J Lab Comp Radiopharm. and Nuklearmedzine. I was also
invited to present the work at the Australian Society of Nuclear Medicine in
April 2013.
10.As mentioned SA has a need for new PET
tracers. It was therefore decided that the Radiochemistry group (under my
guidance) will develop F-18 ethylcholine as prostate cancer imaging agent.
After two years and a big team effort a GMP compliant radiotracer was produced
for a 50 patients phase 1 clinical trial in prostate cancer patients. This was
successfully completed and the radiotracer is now sold to patients by NTP,
Necsa’s commercial subsidiary. Publication of the clinical results will follow
soon.
11.In 2010 it became very obvious that the
increased nr of PET cameras in South Africa were highly underutilized due to
the limitations on F-18 production sites. A Ga-68 generator would be the answer
in the third world setting. What is also of interest in the third world setting
is to selectively detect infection as opposed to inflammation in HIV
compromised patients which present themselves with fever of unknown origin.
Therefore in collaboration with Prof Mike Sathekge at UP a section of the UBI
peptide was evaluated for these purposes. Under my guidance the labelling was
achieved and I facilitated PET imaging studies in monkeys and rabbits after
hours at UP as SA lacks a microPET camera.
All this hard work paid off and we can proudly state that Ga-68
radiolablled UBI(30-41)-NOTA is the world’s first PET infection imaging agent.
Several conference presentations in 2011-2013 were presented as well a high
impact paper in J Nucl Med has recently appeared which demonstrated the
selective uptake in a rabbit infection/inflammation model. A 4:1 infection over
inflammation ratio was achieved. Several
more high impact papers have been submitted and are in the process of review.
Very gratifying results have been achieved.
In both the blood plasma modelling it has been shown a number of times that the
predictions of the model are confirmed in vivo. The same for the establishment
of the universal equation to calculate recoil of in vivo generators. The 2 clinical trials have also been highly
successful.
Conference
Papers
J.R. Zeevaart and N.V. Jarvis, Complexation of trivalent
lanthanides by three diphosphonate ligands in blood plasma
33rd Convention of the South African
Chemical Institute, Cape Town, South Africa 1995.
J.R. Zeevaart, N.V. Jarvis, G.E. Jackson and I. Cukrowski.
Investigation into the use of 166Ho complexed to diphosphonate
ligands as possible radiopharmaceuticals for bone cancer patients.
4th International Symposium on Applied
Bio-inorganic Chemistry (4th ISABC), Cape Town, South Africa, 1997.
N.V. Jarvis, J.R. Zeevaart, , J.M. Wagener, G.E. Jackson
and I. Cukrowski. Blood plasma models (ECCLES) for 153Sm and 166Ho
complexed to diphosphonate ligands.
34th Convention of the South African
Chemical Institute, Durban, South Africa 1998.
J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener, I.C. Dormehl
and R.J. Milner. Comparison between blood plasma models (ECCLES) for 153Sm
and 166Ho complexed to diphosphonate ligands (possible
radiotherapeutic bone agents) and their in
vivo behaviour as studied in non-human primates.
3rd International Conference on Isotopes
(3ICI), Vancouver, Canada 1999.
J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, J.M. Wagener, I.C. Dormehl
and R.J. Milner. Comparison between blood plasma models (ECCLES) for 153Sm
and 166Ho complexed to diphosphonate ligands (possible
radiotherapeutic bone agents) and their in
vivo behaviour as studied in non-human primates.
35th Convention of the South African
Chemical Institute (SACI-2000), Potchefstroom, South Africa 2000.
J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis and J.M. Wagener.
Comparison of the predicted behaviour of 153Sm, 166Ho and
117mSn containing bone agents, employing blood plasma models
(ECCLES), with in vivo results as
studied in animals.
12th International Symposium on
Radiopharmaceutical Chemistry (12thISRC), Interlaken, Switzerland,
2001.
Published in J. Lab. Comp. Radiopharm. 44, suppl. 1,
S799-S801, 2001.
J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, J.M. Wagener, Z.I. Kolar,
R.A.M.J. Claessens. A thermodynamic approach
towards the evaluation and design of bone-seeking radiopharmaceuticals as
illustrated for 117mSn(II)-PEI-MP.
4th International Conference on Isotopes
(4ICI), Cape Town, South Africa 2002.
J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, J.M. Wagener, Z.I. Kolar,
R.A.M.J. Claessens A
thermodynamic approach towards the evaluation and design of bone-seeking
radiopharmaceuticals as illustrated for 117mSn(II)-PEI-MP.
SACI 2002, Port Elizabeth, South Africa, 2002.
W.K.A. Louw, J.R. Zeevaart, Z.I. Kolar, I.C Dormehl, J.M.
Wagener, R. Milner, E. Kilian, F.H.A. Schneeweiss 117mSn and 186Re
radiolabelling of polyethyleneiminomethyl phosphonic acid (PEI-MP), apotential
selective therapeutic bone tumour seeker.
South African Society of Nuclear Medicine,
Stellenbosch, South Africa, 4-7 Dec. 2002.
Published in Nucl. Med. Comm. , 23, p.1223-1224, 2002.
J.R. Zeevaart, W.K.A. Louw, D.R. Jansen, J.M. Wagener, M.F.
Botelho, C. Gomes, L. Metello, A. Abrunhosa, Z.I.Kolar, I.C. Dormehl.
Comparison of the predicted behaviour of 117mSn-APDDMP and the in vivo results as studied in rats.
SACI Inorganic ’03 conference, Roodevallei, Pretoria,
Sout Africa, June 2003.
D.R. Jansen, J.R. Zeevaart, W.K.A. Louw, J.M. Wagener Formation constants for the
complexation of APDDMP with Sn(II).
SACI Inorganic
’03 conference, Roodevallei, Pretoria, Sout Africa, June 2003.
F. Botelho, I. Dormehl, W. Louw, J.R.
Zeevaart, C. Gomes, Z. Kolar, A. Abrunhosa, L. Metello, R. Milner, J. de Lima,
F. Schneeweiss, Polyethyleneiminomethyl phosphonate (PEI-MP) for selectively
targeting bone malignancies,
European Association of Nuclear
Medicine, Amsterdam, the Netherlands, 13 – 27 Aug. 2003.
Published in Eur. J. Nucl. Med.
Mol Imaging 30, suppl. 2, S338, 2003.
J.R. Zeevaart, W. Louw, J.M. Wagener, F. Botelho, C. Gomes, A.
Abrunhosa, L. Metello, Z. Kolar, I. Dormehl, Selective tumour localisation of the bone-seeking
radiopharmaceutical 117mSn(II)-PEI-MP as studied in osteosarcoma
containing mice,
15th International Symposium on
Radiopharmaceutical Chemistry, Sydney, Australia, 10-14 Aug. 2003.
Published in J. Lab. Comp. Radiopharm. 46, suppl. 1,
S100, 2003
J.R. Zeevaart, W. Louw, J.M. Wagener, I. Dormehl, E. Killian. Selective carriers for the conversion electron
radionuclides, 117mSn and 195mPt as potential therapeutic
bone agents,
12th International Congress on Radiation
Research, Brisbane, Australia, 17-21 Aug. 2003.
Z.I. Kolar, R.A.M.J. Claessen, J.R. Zeevaart and G.C.
Krijger, Interfacial chemistry in aqueous tin-bisphosphonate / hydroxyapatite
systems,
17th Conference of the European Colloid
& Interface Science Society, Firenze, Italy, 21 -26 Sept. 2003.
F.H.A. Schneeweiss, I.C Dormehl, W.K.A. Louw, J.R. Zeevaart,
Z.I. Kolar, F. Botelho, J Wagener, R. Milner, A Abrunhosa, C. Gomes, L.
Metello, L de Lima, Radioiaktive
Markierung von Polyethyleniminomethyl-phosphonsäure (PEI-MP) mit 117mSn
und dessen Reaktion mit auf Nacktmäusen transplantierten Osteosarcoma,
7. Jahrestagung der
Gesellschaft fur Biologische Strahlenforschung, 31 March – 2 April 2004, Darmstadt,
Germany.
Published in Proceedings
the of the above, ISBN 3-00-013476-X
L. Metello , J.R Zeevaart, W.K.A.
Louw, D.R. Jansen, J.M. Wagener, M.F. Botelho, C. Gomes, A. Abrunhosa, Z.I. Kolar, I.C. Dormehl. In vivo
and in vitro biodistribution studies of 117mSn-APDDMP in Wistar rats
12th European Symposium on
Radiopharmacy and Radiopharmaceuticals, Sept
9 - 12, 2004 Gdansk, Poland.
Zeevaart JR, Louw
WKA, Jansen DR, Botelho MF, Gomes C, Metello L, Abrunhosa A, Kolar ZI, Krijger
GC, Dormehl IC. Comparison of tumour uptake in different types of osteosarcoma mice as
studied with the potential bone-seeking radiopharmaceutical, 117mSn(II)-PEI-MP
INTERNATIONAL CONGRESS OF RADIOPHARMACY
& RADIOPHARMACEUTICAL CHEMISTRY, Sept 25-29, 2004 Istanbul, Turkey, Published in World J. Nucl. Med. 3, 237 (2004)
J.R. Zeevaart, S.A. Shady, A. Goede, M.M. Phetoe, Determination of adsorption characteristics for
different Cs selective resins
J.M. Wagener, O. Perera, J.R.
Zeevaart; Production of I125-progesterone tracer. (5th International
conference on Isotopes. April 25-29, 2005, Brussels,Belguim)
J.M. Wagener, J.R. Zeevaart, M. Neves, M.C.
Costa, C. Rodrigues, M.K. Dithebe, O. Knoesen and W.K. Louw. 99mTC LABELED BIGUANIDE DERIVATIVES:
CHEMICAL SPECIATION MODELLING OF AND EVALUATION IN VERVETS.
16th Int. Sym. on Radiopharmaceutical Chem.
in Iowa City, USA, June 24-28, 2005.
Published in J. Lab. Comp. Radiopharm. 48, suppl. 1,
S260, 2005.
M. F. Botelho, F. Caramelo, C. Gomes, J. R. Zeevaart , W.K.A.
Louw , I.C. Dormehl, Z.I. Kolar , G.C. Krijger ,
R.J. Milner. Biodistribution and Dosimetric Calculations for 117mSn-APDDMP,
a Potential Osteosarcoma Treatment Agent.
Primeiras Jornadas Luso
Brasileiras de Protecção Contra Radiações e Décimas Primeiras Jornadas Portuguesas
de Protecção Contra Radiações (1st Luso-Brasilian Meeting of Protection against
Radiation and XI Portuguese Meeting of Protection against Radiation), Lisbon 25
November, 2005.
I. Dormehl, W. Louw , J.R. Zeevaart, Z.
Kolar, F. Botelho, J. Wagener, R. Milner, A. Abrunhosa, C. Gomes, L. Metello, F. Schneeweiss, J. de Lima. 117mSn
and 186Re radiolabelling of Polyethyleneiminomethyl phosphonate
(PEI-MP), followed by in vivo targeting of induced osteosarcoma in nude mice.
Radioactive isotopes in clinical medicine and research
- 27th Int symposium, Bad Gastein, Austria, 11-14 January 2006.
L. Metello, M.F. Botelho, J.R. Zeevaart , I.C.
Dormehl, W.K.A. Louw , F. Caramelo, C. Gomes, M. Neves, Z.I. Kolar
, G.C. Krijger, R.J. Milner, Comparison
of the polyphosphonate; PEI-MP labeled with 117mSn and 186Re
as potential therapeutic bone agents,
European Symposium on Radiopharmacy and
Radiopharmaceuticals, Lucca, Italy, 30 March- 2 April 2006.
Published in Q. J. Nucl. Med.
50 suppl. 1 p 49, 2006
F. Botelho, J.R. Zeevaart, .I Dormehl, W.
Louw, F. Caramelo, L. Metello, C. Gomes, M. Neves, C. Sena, A.N. Abrantes, Z. Kolar, G. Krijger, Dosimetric evaluations of the
polyphosphonate; PEI-MP labeled with Sn-117m, Re-186 and Tc-99m as
potential diagnosis/therapeutic bone
agents. European Association of Nuclear Medicine, Athens, Greece, the
Netherlands, 1-3 October 2006.
Published in Eur. J. Nucl. Med. Mol Imaging 33, suppl. 2, S309, 2006.
J.R. Zeevaart, J.M. Wagener, M.J. Nell, E. Kilian, M.A. Mamo, M. Layh,
M. Coyanis, C.E.J. van Rensburg; Determination of the biodistribution of
Au-compounds (intended as potential chemotherapeutics) by the use of
radiolabelled tracers.
2nd CONFERENCE on Imaging in Pre-clinical & Clinical Drug
Development , Boston, USA, March 16th and 17th
2007.
J.R. Zeevaart,, D.R. Jansen , Z.I. Kolar, J.A. Peters, G.C.
Krijger Towards a
Radiopharmaceutical for Palliative Treatment of Metastatic Bone Pain: a Novel 117mSn(SnII or SnIV)-Polymer Complex. 17th International Symposium on
Radiopharmaceutical Sciences, Aachen, Germany from 30 April – 4 May 2007.
Published in J. Lab. Comp.
Radiopharm. 50, suppl. 1, S452, 2007.
J.R. Zeevaart , D.R. Jansen,
Z.I. Kolar, J.A. Peters , G.C. Krijger , Progress made with potential
117m Sn [Sn (II)] Radiopharmaceuticals aimed at treating secondary bone
metastasis: Clarifying their in vivo oxidation state. INORG 007 conference of
the South African Chemical Institute, Club Mykonos, West Coast 8-12 July 2007.
Invited lecture
F. Botelho, J.R. Zeevaart, D.R. Jansen, A. Turtio, A.M.
Abrantes, Z.I. Kolar, M.A. Neves, F.H.A. Scheneeweiss, G.C. Krijger, I.C.
Dormehl. Comparison of the sizes of the
potential therapeutic bone agents, the
polyphosphonate PEI-MP labeled with 117mSn and 186Re Dosimetric
evaluations of the polyphosphonate. European Association of Nuclear Medicine,
Copenhagen, Denmark, 13-17 October 2007.
Published in Eur. J. Nucl. Med. Mol Imaging 34, suppl. 2, P354, 2007.
J.R.Zeevaart , J.M.Wagener , M. Neves , M.C. Costa , C. Rodrigues
,O. Knoesen , M.K. Dithebe , E. Kilian , I. Cukrowski 99m Tc labeled biguanide
derivatives: chemical speciation
modeling thereof and evaluation in vervets.
RheManTec International conference 19-24 November 2007
Bloemfontein.
D.R. Jansen, J.R. Zeevaart, Z.I. Kolar, K. Djanashvilik, J. A.
Peters, G.C. Krijger, Towards understanding the in vivo behaviour of potential
(117m sn)sn-based radiopharmaceuticals aimed at treating secondary bone
metastasis.
South African Young Nuclear Professional
Society: 6 November 2007: Alpha Conference Centre.
J.R. Zeevaart, D.R. Jansen, Z.I. Kolar, G.C. Krijger Sn-117m PEI-MP (N,N’,N’-trimethylenephosphonate-polyethyleneimine) as
potential bone metastasis agent; Adsorption behavior on hydroxyapatite.
6th International conference on Isotopes, 12-16 May 2008, Seoul, S.
Korea.
C.C.P. Wagener, J.R. Zeevaart.
The labeling of fluoroquinolones with F-18.
6th International conference on Isotopes, 12-16 May 2008, Seoul, S.
Korea.
Z. Szucs, J. van Rooyen, J.R. Zeevaart. A possible
in vivo generator 103Pd/103mRh - Recoil considerations.
6th International conference on Isotopes, 12-16 May 2008, Seoul, S.
Korea.
J.M. Wagener, J.R. Zeevaart, M.J. Nell, E. Kilian, M.A. Mamo, M.
Layh, M. Coyanis, C.E.J. van Rensburg. Determination
of the biodistribution of Au-compounds (intended as potential
chemotherapeutics) by the use of radiolabelled tracers.
6th International conference on Isotopes, 12-16 May 2008, Seoul, S.
Korea.
S.M Rubow, F. De Klerk, E.
Kilian, O. Knoesen, J.M. Wagener, J. Naidoo, J.R. Zeevaart. EVALUATION OF BIODISTRIBUTION
OF Tc-99m IgG FOR INFECTION IMAGING.
SA Society for Nucl. Med.
21-26 August 2008, Society of Nuclear Medicine, Windhoek, Namibia.
J. R. Zeevaart, D. R. Jansen, Z. I. Kolar, G. C. Krijger.Sn-117m PEI-MP
(N,N’,N’-trimethylenephosphonate-polyethyleneimine) as potential bone
metastasis agent; Adsorption behaviour on
hydroxyapatite,; South African Society of Nuclear
Medicine, 21-26 August 2008, Windhoek, Namibia.
Z. Szucs , D.
Steyn,E. Vermeulen, I.J. Van der Walt, K. Moodley, S. Verryn. J.R. Zeevaart. Separation
of 103Pd from metal Rh by thermal diffusion impossible. 4
NRC7 - SEVENTH INTERNATIONAL CONFERENCE ON NUCLEAR AND RADIOCHEMISTRY Budapest,
Hungary 24-29 August 2008
JR Zeevaart, JM Wagener, J Naidoo, O Knoesen, E Kilian, J Perils,
SM Rubow,Technetium in the third world setting.R&D in South Africa.
Int Symposium on Tc and Re, 7-10 Oct 2008, Port
Elizabeth, South Africa
Invited Plenary lecture
J. Topkin, P. Mitchel, Z. Szucs, J.R. Zeevaart, New method for preparing 35S in
the form as a sulfite to be used as tracer in medical and physiological
research Tracer 5, 2-6 November 2008, Tiradentes-MG, Brazil.
W.G. Augustyn, J.B. Wagener, J.T. Nel, W. Meyer, J.R.
Zeevaart, Z. Szucs, A. Goede. Nano@Necsa;
Nano Afica 2009
International Conference, 1-4 February 2009, CSIR conference centre, Pretoria,
South Africa.
D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger.
More with less: Possible methods of producing 117mSn with high
specific activity, 18th International Symposium on Radiopharmaceutical
Sciences, 12-17 July 2009,Edmonton, Canada.
Published in J. Lab. Comp.
Radiopharm. 52, suppl. 1, S452, 2009.
N.L. Dlamini, X.Y Mbianda, Z.
Szucs, J.R.Zeevaart. Synthesis and characterization of bisphosphonate
conjugated carbon nanomaterials as a potential system for the treatment of
secondary bone cancer. Biomaterials-Africa
2009 Conference, 20-22 September 2009, Pretoria, South Africa.
D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger,
More
with less: Possible methods of producing 117mSn with high specific
activity, 18th
International symposium on radiopharmaceutical sciences conference in Edmonton,
Canada, 12 – 17 July 2009.
J.R. Zeevaart, D.R. Jansen, K Gabanamotse, Z.I. Kolar, G.C. Krijger, An in vitro instead of in vivo approach to develop 117mSn based
bone-seeking radiopharmaceuticals as studied for Sn(II) and Sn(IV) complexes of
the polymer polyethyleniminomethyl phosphonic acid(PEI-MP); IAEA Technical Meeting on Therapeutic
Radiopharmaceuticals IAEA HQ, Vienna, Austria 16 to 20 November 2009.
N.L. Dlamini, X.Y. Mbianda, J.R. Zeevaart,
Z. Szucs. Synthesis and
characterisation of bisphosphonates conjugated carbon nanotubes conjugates as a
potential treatment for secondary bone cancer. “ICS-UNIDO conference
on Advanced diagnostics and drug-delivery at the nanoscale: state of the art
and possible applications to orphan diseases” 13-15 October 2009. Trieste,
Italy.
Published in
European Cells and Materials Vol. 19. Suppl. 1, 2010 (page 21) ISSN 1473-2262.
J.R. Zeevaart, Z. Szucs, S. Takacs, K Gabanamotse, N.V. Jarvis. In vivo generators – recoil and conversion electrons
considerations. RadChem 2010, Marianske Lazne, Czech
republic,18-23 April 2010.
Invited lecture
J Suthiram, Kanyisa Mhlaba, Jan Rijn Zeevaart,
Hendrik G Visser and Andreas Roodt.
International
symposium on Technetium and other radiometals in chemistry and medicine, Brixen
Bressanone, Italy September 8 – 11, 2010.
Z Szucs, M
Sathekge, B Marjanovic-Painter, JM Wagener, T Sellot, CCP Wagener, JR
Zeevaart. Synthesis and biodistribution of I-131 labelled 4-iodophenyl
acetic acid. 10 th Congress of WNFMB, Cape Town South Africa, 18 – 23 September
2010.
Published in World Journal of Nuclear Medicine –
Volume 9, September 2010, S169
D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar,
G.C. Krijger More with less: Possible
methods of producing 117mSn with high specific activity
10 th Congress of
WNFMB, Cape Town South Africa, 18 – 23 September 2010
Published in World Journal of Nuclear Medicine –
Volume 9, September 2010, S41
J.R. Zeevaart, Z. Szucs, S. Takacs, DR Jansen, N.V. Jarvis. Recoil
and conversion electrons considerations of the 166Dy/166Ho
in vivo generator. 2nd
International Conference on the Application of Radiotracers
in Chemical, Environmental and Biological Sciences
(ARCEBS 10) Kolkata, India, 8-13 November 2010.
Invited Plenary lecture
T
Ebenhan, Z Szucs, K. Cimpeanu, D
Dudu J.R. Zeevaart. Production
of 68Ge from natural Zink by cyclotron 1st World Congress on Gallium-68 and Peptide
Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized
Medicine, Zentralklinik
Bad Berka, Germany – June 23-26, 2011.
Published in World Journal of Nuclear Medicine –
Volume 10, June 2011, 73
T
Ebenhan, N.
Chadwick, T. Govender, H.G. Kruger, M. Sathekge, J.R.
Zeevaart. Gallium-68 labelling of NOTA-peptide conjugates for imaging
infection – especially tuberculosis. 1st World Congress on Gallium-68 and Peptide
Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized
Medicine, Zentralklinik
Bad Berka, Germany – June 23-26, 2011.
Published in World Journal of Nuclear Medicine –
Volume 10, June 2011, 86
David R Jansen, Jan Rijn Zeevaart, Zvonimir I Kolar,
Gerard C Krijger. An in vitro approach to evaluate and develop potential 117m
Sn based bone-seeking radiopharmaceuticals. 2nd Annual SA Young
Scientists Conference, 26 – 27 September 2011, Pretoria, South Africa
J Suthiram, HG Visser, JR Zeevaart, A Roodt.
Crystallographic and kinetic studies of Re(I)-tricarbonyl complexes with nN,O)-donar
bidentate ligands. 2nd Annual SA Young Scientists Conference, 26 –
27 September 2011, Pretoria, South Africa
LC Sepini, DR Jansen, NV Jarvis JR Zeevaart. Towards
establishing a blood plasma model for Lu(III). 2nd Annual SA Young
Scientists Conference, 26 – 27 September 2011, Pretoria, South Africa
DR Jansen, LC Sepini, NV Jarvis, JR Zeevaart.
Towards establishing a blood plasma model for Lu(III). 7th
International Conference on Isotopes, Russia 4-8 September 2011.
C Driver, MI Parker, R Hunter, JR Zeevaart, The
Development of a Gluco-Albumin Macromolecule as a Specific Targeting Agent for
Tumors SANHARP 2nd Annual postgraduate conference Cape Town
12-14 October 2011
S.M. Ferreira, A.M. Abrantes, L.F. Metello, J.R. Zeevaart, W.K.A. Louw, I.C. Dormehl, M.F. Botelho. 188Re-PEI-MP as a potential
agent for metabolic radiotherapy. European Association of Nuclear Medicine, Birmingham,
UK, 15-19 October 2011.
Published in Eur.
J. Nucl. Med. Mol Imaging 38, suppl.
2, S213, 2011
B Kweto, DR Groot,
J Suthiram, L Stassen, JR Zeevaart. The use of ammonium carbonate as lixiviant
in uranium leaching. ALTA 2012
conference on nickel/cobalt/copper, uranium & gold. 26 May- 2 June 2012,
Perth, Australia
Published
in Proceeding of Uranium sessions at ALTA 2012, ISBN: 978-0-9871262-4-5, p.139-149
T.
Ebenhan T. Govender, G.H. Kruger, T. Pulker, V.Naidoo, J.R. Zeevaart and M. Sathekge.
Synthesis of 68Ga-NOTA-UBI30-41 and in
vivo Biodistribution in vervet Monkeys towards potential PET/CT Imaging of
Infection. SNM 2012 annual meeting, 9-13 June 2012,Miami beach, Florida, USA. Published in J. Nucl. Med. 2012 vol 53, suppl 1, P1520,
JR Zeevaart, ‘Radiospoorders – 'n
visualiseringstegniek behulpsaam om medisyne(middels) vinniger te ontwikkel’ Simposium 2012 of the ‘Suid Afrikaanse Akademie
vir Wetenskap en Kuns’
21-22 June 2012,
Pretoria, SA
Invited keynote lecture
Wagener J.M., Zinn C., Marjanovic-Painter B., Soni N., Perkins G.,
Sathekge M.M., Smith S.V, Zeevaart J.R., Production of high specific
activity 195mPt-Cisplatinum at Necsa for Phase 0 clinical trial in
healthy individuals subjects. 11th International Symposium on the Synthesis and
Applications of Isotopes and Isotopically Labelled Compounds (IIS XI), Heidelberg,
Germany (9-13 September 2012)
Zeevaart J.R, Szucs Z. Takacs S., van Rooyen J. , Jansen
D., Recoil and conversion electron
implications to be taken into account in the design of therapeutic
radiopharmaceuticals utilising in vivo
generators. NRC-8,
16-20 September 2012, Como, Italy
Invited lecture
Ferreira S., Lranjo M., Abrantes A.M., Brito A.F., Metello L., Zeevaart
J.R., Louw W., Dormehl I., Botelho M.F.
A comparative study to analyse the potential of 99mTc-PEI-MP for
diagnosis and 188Re-PEI-MP for therapy of bladder carcinoma and osteosarcoma. 5th Annual meeting of the World
Molecular Imaging Congress, Dublin Ireland, 5-8 September 2012
Ebenhan T., Zeevaart
J.R., Govender T., Kruger H.G., Pulker T., Sathekge M.M, Preparation of a
promising infection PET/CT imaging biomarker: 68Ga-labeled
UBI30-41-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility study in
a vervet monkey model. South African Society of
Nuclear Medicine, Parys, South Africa, 21-24 September 2012
Wagener J., Zinn C., Marjanovic-PainterB., Soni N., Perkins
G. , Sathekge M. , Smith S.V. , Zeevaart J.R.,
Production of high specific activity 195mPt-Cisplatin at NECSA for
Phase 0 clinical trial in healthy individuals subjects. South African
Society of Nuclear Medicine, Parys,
South Africa, 21-24 September 2012.
vd Westhuizen D., Wagener C.P., van Otterlo
A.L., Sello T. The construction
and configuration of a “homemade” remote synthesis unit for the synthesis of
radiolabelled [F-18] Fallypride tracer. South African Society of Nuclear Medicine,Parys,
South Africa, 21-24 September 2012.
J.R. Zeevaart, Two sides of the
radiochemistry coin: Radiopharmaceuticals and Biological Radiotracers. SACI
Centenary Lectures, UP, Pretoria, SA, 28 September 2012
Invited keynote lecture & NWU (Mafikeng campus) research
day
Wagener J.M., Zinn C., Marjanovic-Painter B., Soni N., Perkins G.,
Sathekge M.M., Smith S.V, Zeevaart J.R., Production
of high specific activity 195mPt-Cisplatinum at Necsa for pahse 0 clinical
trials in healthy individuals, ANZSNM, Perth Australia, 11 – 15 April 2013
Invited lecture
J.R. Zeevaart, Z. Szucs, S. Takacs, DR Jansen. Recoil and conversion electron implications to be taken into account in
the design of therapeutic radiopharmaceuticals utilising in vivo generators.
ANZSNM, Perth Australia, 11 – 15 April 2013
Jansen, David
R., Sepini, Lebogang C.
Jarvis, Neil V. Zeevaart, Jan Rijn A thermodynamic
evaluation of 1,4,7,10-tetraazacyclododecane-1,4,7,10 tetra(methane-phosphonic
acid) (DOTP) as a component of the bone-seeking radiopharmaceutical [177Lu]Lu(ΙII)-DOTP,
towards establishing blood plasma model for Lu(III). 20th International Symposium on
Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17 May 2013
Published in J Label Compd
Radiopharm 2013; 56: S439
Jansen, David
R., Sepini, Lebogang C.
Jarvis, Neil V. Zeevaart, Jan Rijn Complexation studies of
[177Lu]Lu(ΙII) with ethylenediaminetetra(methylene phosphonic acid) (EDTMP) as
a potential agent for bone pain palliative radiotherapy. 20th
International Symposium on Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17
May 2013
Published in J Label Compd
Radiopharm 2013; 56: S440
J R Zeevaart, S Winks, M S Sonopo SYNTHESIS AND
CARBON-14 RADIOLABELLING OF A POTENTIAL ANTI-TB COMPOUND International
Isotope Society - Central European Division workshop September
26-2,72013 Bad Soden, Germany
Thomas Ebenhan1,5, Jacobus D. Venter2,
Daniel J. Goosen3, JanRijn Zeevaart4, Neil Jarvis5,
Mike Sathekge1 NOTA conjugation to UB129-41 allows highly
selective infection imaging with PET/CT:
A feasibility study in rabbits. World molecular Imaging congress, 2013, 18-21
September 2013, Savannah, USA
Publications in proceedings
J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener, I.C. Dormehl
and R.J. Milner. Comparison between blood plasma models (ECCLES) for 153Sm
and 166Ho complexed to diphosphonate ligands (possible
radiotherapeutic bone agents) and their in
vivo behaviour as studied in non-human primates. Published in Isotope Production and Applications in the 21st
Century, N.R. Stevenson, World Scientific, 2000, 403-406,
ISBN:981-02-4200-x.
J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis and J.M. Wagener.
Comparison of the predicted behaviour of 153Sm, 166Ho and
117mSn containing bone agents, employing blood plasma models
(ECCLES), with in vivo results as
studied in animals.
12th International Symposium on
Radiopharmaceutical Chemistry (12thISRC), Interlaken, Switzerland,
2001.
Published in J. Lab. Comp. Radiopharm. 44, suppl. 1,
S799-S801, 2001.
W.K.A. Louw, J.R. Zeevaart, Z.I. Kolar, I.C Dormehl, J.M.
Wagener, R. Milner, E. Kilian, F.H.A. Schneeweiss 117mSn and 186Re
radiolabelling of polyethyleneiminomethyl phosphonic acid (PEI-MP), apotential
selective therapeutic bone tumour seeker.
South African Society of Nuclear Medicine,
Stellenbosch, South Africa, 4-7 Dec. 2002.
Published in Nucl. Med. Comm. , 23, p.1223-1224, 2002.
F. Botelho, I. Dormehl, W. Louw, J.R.
Zeevaart, C. Gomes, Z. Kolar, A. Abrunhosa, L. Metello, R. Milner, J. de Lima,
F. Schneeweiss, Polyethyleneiminomethyl phosphonate (PEI-MP) for selectively
targeting bone malignancies,
European Association of Nuclear
Medicine, Amsterdam, the Netherlands, 13 – 27 Aug. 2003.
Published in Eur. J. Nucl. Med.
Mol Imaging 30, suppl. 2, S338, 2003.
J.R. Zeevaart, W. Louw, J.M. Wagener, F. Botelho, C. Gomes, A.
Abrunhosa, L. Metello, Z. Kolar, I. Dormehl, Selective tumour localisation of the bone-seeking
radiopharmaceutical 117mSn(II)-PEI-MP as studied in osteosarcoma
containing mice,
15th International Symposium on
Radiopharmaceutical Chemistry, Sydney, Australia, 10-14 Aug. 2003.
Published in J. Lab. Comp. Radiopharm. 46, suppl. 1,
S100, 2003
F.H.A. Schneeweiss, I.C Dormehl, W.K.A. Louw, J.R. Zeevaart,
Z.I. Kolar, F. Botelho, J Wagener, R. Milner, A Abrunhosa, C. Gomes, L.
Metello, L de Lima, Radioiaktive
Markierung von Polyethyleniminomethyl-phosphonsäure (PEI-MP) mit 117mSn
und dessen Reaktion mit auf Nacktmäusen transplantierten Osteosarcoma,
7. Jahrestagung der
Gesellschaft fur Biologische Strahlenforschung, 31 March – 2 April 2004,
Darmstadt, Germany.
Published in Proceedings
the of the above, ISBN 3-00-013476-X
Zeevaart JR, Louw
WKA, Jansen DR, Botelho MF, Gomes C, Metello L, Abrunhosa A, Kolar ZI, Krijger
GC, Dormehl IC. Comparison of tumour uptake in different types of osteosarcoma mice as
studied with the potential bone-seeking radiopharmaceutical, 117mSn(II)-PEI-MP
INTERNATIONAL CONGRESS OF RADIOPHARMACY
& RADIOPHARMACEUTICAL CHEMISTRY, Sept 25-29, 2004 Istanbul, Turkey, Published in World J. Nucl. Med. 3, 237 (2004)
J.M. Wagener, J.R. Zeevaart, M. Neves, M.C.
Costa, C. Rodrigues, M.K. Dithebe, O. Knoesen and W.K. Louw. 99mTC LABELED BIGUANIDE DERIVATIVES:
CHEMICAL SPECIATION MODELLING OF AND EVALUATION IN VERVETS.
16th Int. Sym. on Radiopharmaceutical Chem.
in Iowa City, USA, June 24-28, 2005.
Published in J. Lab. Comp. Radiopharm. 48, suppl. 1,
S260, 2005.
J.R. Zeevaart, S.A. Shady, A. Goede, M.M. Phetoe, Determination of adsorption characteristics for
different Cs selective resins,
Published in
Proceedings of the 5th International Conference on Isotopes,
Editors; H. Bonet, B.J. Allen, C. Chemaly, Medimond, 2005, ISBN 88-7587-186-8,
227-230.
L. Metello, M.F. Botelho, J.R. Zeevaart , I.C.
Dormehl, W.K.A. Louw , F. Caramelo, C. Gomes, M. Neves, Z.I. Kolar
, G.C. Krijger, R.J. Milner, Comparison
of the polyphosphonate; PEI-MP labeled with 117mSn and 186Re
as potential therapeutic bone agents,
European Symposium on Radiopharmacy and
Radiopharmaceuticals, Lucca, Italy, 30 March- 2 April 2006.
Published in Q. J. Nucl. Med.
50 suppl. 1 p 49, 2006
F. Botelho, J.R. Zeevaart, .I Dormehl, W.
Louw, F. Caramelo, L. Metello, C. Gomes, M. Neves, C. Sena, A.N. Abrantes, Z. Kolar, G. Krijger, Dosimetric evaluations of the
polyphosphonate; PEI-MP labeled with Sn-117m, Re-186 and Tc-99m as
potential diagnosis/therapeutic bone
agents. European Association of Nuclear Medicine, Athens, Greece, the
Netherlands, 1-3 October 2006.
Published in Eur. J. Nucl. Med. Mol Imaging 33, suppl. 2, S309, 2006.
J.R. Zeevaart,, D.R. Jansen , Z.I. Kolar, J.A. Peters, G.C.
Krijger Towards a
Radiopharmaceutical for Palliative Treatment of Metastatic Bone Pain: a Novel
117mSn(SnII or SnIV)-Polymer Complex. 17th International Symposium on
Radiopharmaceutical Sciences, Aachen, Germany from 30 April – 4 May 2007.
Published in J. Lab. Comp.
Radiopharm. 50, suppl. 1, S452, 2007.
F. Botelho, J.R. Zeevaart, D.R. Jansen, A. Turtio, A.M.
Abrantes, Z.I. Kolar, M.A. Neves, F.H.A. Scheneeweiss, G.C. Krijger, I.C.
Dormehl. Comparison of the sizes of the
potential therapeutic bone agents, the
polyphosphonate PEI-MP labeled with 117mSn and 186Re Dosimetric
evaluations of the polyphosphonate. European Association of Nuclear Medicine,
Copenhagen, Denmark, 13-17 October 2007.
Published in Eur. J. Nucl. Med. Mol Imaging 34, suppl. 2, P354, 2007.
Z. Szucs ,
D. Steyn, E. Vermeulen, I.J. Van der Walt, K. Moodley, S. Verryn. J.R.
Zeevaart. Separation of 103Pd from metal
Rh by thermal diffusion impossible. 7th International Conference on Nuclear and
Radiochemistry. NRC 7. Budapest, Hungary, 24-29 Aug., 2008.
Published in the Proceedings.
CD-ROM 0 (2008)1-1./ 0.000
N.L. Dlamini, X.Y. Mbianda, J.R. Zeevaart,
Z. Szucs. Synthesis and
characterisation of bisphosphonates conjugated carbon nanotubes conjugates as a
potential treatment for secondary bone cancer. “ICS-UNIDO conference
on Advanced diagnostics and drug-delivery at the nanoscale: state of the art
and possible applications to orphan diseases” 13-15 October 2009. Trieste,
Italy.
Published in
European Cells and Materials Vol. 19. Suppl. 1, 2010 (page 21) ISSN 1473-2262.
D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger.
More with less: Possible methods of producing 117mSn with high
specific activity, 18th International Symposium on Radiopharmaceutical
Sciences, 12-17 July 2009,Edmonton, Canada.
Published in J. Lab. Comp.
Radiopharm. 52, suppl. 1, S452, 2009.
Z Szucs, M
Sathekge, B Marjanovic-Painter, JM Wagener, T Sellot, CCP Wagener, JR
Zeevaart. Synthesis and biodistribution of I-131 labelled 4-iodophenyl
acetic acid. 10 th Congress of WNFMB, Cape Town South Africa, 18 – 23 September
2010.
Published in World Journal of Nuclear Medicine –
Volume 9, September 2010, S169
D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar,
G.C. Krijger More with less: Possible
methods of producing 117mSn with high specific activity
10 th Congress of
WNFMB, Cape Town South Africa, 18 – 23 September 2010
Published in World Journal of Nuclear Medicine –
Volume 9, September 2010, S41
T
Ebenhan, Z Szucs, K. Cimpeanu, D
Dudu J.R. Zeevaart. Production
of 68Ge from natural Zink by cyclotron 1st World Congress on Gallium-68 and Peptide
Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized
Medicine, Zentralklinik
Bad Berka, Germany – June 23-26, 2011.
Published in World Journal of Nuclear Medicine –
Volume 10, June 2011, 73
T
Ebenhan, N.
Chadwick, T. Govender, H.G. Kruger, M. Sathekge, J.R. Zeevaart. Gallium-68
labelling of NOTA-peptide conjugates for imaging infection – especially
tuberculosis. 1st World Congress on
Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on
the Way to Personalized Medicine, Zentralklinik
Bad Berka, Germany – June 23-26, 2011.
Published in World Journal of Nuclear Medicine –
Volume 10, June 2011, 86
S.M. Ferreira, A.M. Abrantes, L.F. Metello, J.R. Zeevaart, W.K.A. Louw, I.C. Dormehl, M.F. Botelho. 188Re-PEI-MP as a potential
agent for metabolic radiotherapy. European Association of Nuclear Medicine, Birmingham,
UK, 15-19 October 2011.
Published in Eur.
J. Nucl. Med. Mol Imaging 38, suppl.
2, S213, 2011
B Kweto, DR Groot,
J Suthiram, L Stassen, JR Zeevaart. The use of ammonium carbonate as lixiviant
in uranium leaching. ALTA 2012
conference on nickel/cobalt/copper, uranium & gold. 26 May- 2 June 2012,
Perth, Australia
Published
in Proceeding of Uranium sessions at ALTA 2012, ISBN: 978-0-9871262-4-5, p.139-149
T.
Ebenhan T. Govender, G.H. Kruger, T. Pulker, V.Naidoo, J.R. Zeevaart and M.
Sathekge. Synthesis of 68Ga-NOTA-UBI30-41 and in vivo Biodistribution in vervet Monkeys towards potential PET/CT
Imaging of Infection. SNM 2012 annual meeting, 9-13 June 2012, Miami beach,
Florida, USA. Published in J. Nucl. Med. 2012 vol 53, suppl 1,
P1520,
Jansen, David
R., Sepini, Lebogang C. Jarvis,
Neil V. Zeevaart, Jan Rijn A thermodynamic
evaluation of 1,4,7,10-tetraazacyclododecane-1,4,7,10 tetra(methane-phosphonic
acid) (DOTP) as a component of the bone-seeking radiopharmaceutical [177Lu]Lu(ΙII)-DOTP,
towards establishing blood plasma model for Lu(III). 20th International Symposium on
Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17 May 2013
Published in J Label Compd
Radiopharm 2013; 56: S439
Jansen, David
R., Sepini, Lebogang C.
Jarvis, Neil V. Zeevaart, Jan Rijn Complexation studies of
[177Lu]Lu(ΙII) with ethylenediaminetetra(methylene phosphonic acid) (EDTMP) as
a potential agent for bone pain palliative radiotherapy. 20th
International Symposium on Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17
May 2013
Published in J Label Compd
Radiopharm 2013; 56: S440
Wagener J.M., Zinn C., Marjanovic-Painter B., Soni N., Perkins G.,
Sathekge M.M., Smith S.V, Zeevaart J.R., Production
of high specific activity 195mPt-Cisplatinum at Necsa for pahse 0 clinical
trials in healthy individuals, ANZSNM, Perth Australia, 11 – 15 April 2013
Published in Internal Medicine
Journal. 2013; 43 (S1), 14-15
J.R. Zeevaart, Z. Szucs, S. Takacs, DR Jansen. Recoil and conversion electron implications to be taken into account in
the design of therapeutic radiopharmaceuticals utilising in vivo generators.
ANZSNM, Perth Australia, 11 – 15 April 2013
Published in Internal Medicine
Journal. 2013; 43 (S1), 37
Thomas Ebenhan1,5, Jacobus D. Venter2,
Daniel J. Goosen3, JanRijn Zeevaart4, Neil Jarvis5,
Mike Sathekge1 NOTA conjugation to UB129-41 allows highly
selective infection imaging with PET/CT:
A feasibility study in rabbits. World molecular Imaging congress, 2013, 18-21
September 2013, Savannah, USA
Papers Refereed
10
Theses Refereed
7 MSc & 2 PhD
Editorship
Guest Editor, Journal of
Radioanalytical and Nuclear Chemistry, 257,
No.1, July 2003
Scientific committee
Chair and Member of 4ICI
(4th International Conference on Isotopes) scientific advisory
committee, Cape Town, March 2002
Member of 5ICI (5th
International Conference on Isotopes) scientific advisory committee, Brussels,
April 2005
Member of 6ICI (6th
International Conference on Isotopes) scientific advisory committee, Seoul, May
2008